Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00651482
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:36.665061+00:00
Published At
2014-07-29T00:00:00+00:00
Record Updated At
2017-04-11
Results Posted At
2014-07-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Kidney Neoplasms", "Kidney (Renal Cell) Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-04-11"
protocolSection.identificationModule.nctId
"NCT00651482"
protocolSection.identificationModule.officialTitle
"Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2014-07-29"

Study condition terms

  • Kidney Neoplasms (protocolSection.conditionsModule.conditions)
  • Kidney (Renal Cell) Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.